Your browser doesn't support javascript.
loading
The complex HLA-E-nonapeptide in Behçet disease.
Castaño-Núñez, Ángel Luís; Montes-Cano, Marco-Antonio; García-Lozano, José-Raúl; Ortego-Centeno, Norberto; García-Hernández, Francisco José; Espinosa, Gerard; Graña-Gil, Genaro; Sánchez-Bursón, Juan; Juliá, María Rosa; Solans, Roser; Blanco, Ricardo; Barnosi-Marín, Ana-Celia; Gómez de la Torre, Ricardo; Fanlo, Patricia; Rodríguez-Carballeira, Mónica; Rodríguez-Rodríguez, Luis; Camps, Teresa; Castañeda, Santos; Alegre-Sancho, Juan-Jose; Martín, Javier; González-Escribano, María Francisca.
Afiliação
  • Castaño-Núñez ÁL; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
  • Montes-Cano MA; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
  • García-Lozano JR; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
  • Ortego-Centeno N; Department of Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain.
  • García-Hernández FJ; Department of Internal Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Espinosa G; Department Autoimmune Diseases, Hospital Universitari Clínic, Barcelona, Spain.
  • Graña-Gil G; Department of Rheumatology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain.
  • Sánchez-Bursón J; Department of Rheumatology, Hospital Universitario de Valme, Sevilla, Spain.
  • Juliá MR; Department of Immunology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Solans R; Department of Internal Medicine, Autoimmune Systemic Diseases Unit, Hospital Vall d'Hebron, Universidad Autonoma de Barcelona, Barcelona, Spain.
  • Blanco R; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Barnosi-Marín AC; Department of Internal Medicine, Complejo Hospitalario Torrecárdenas, Almería, Spain.
  • Gómez de la Torre R; Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Fanlo P; Department of Internal Medicine, Hospital Virgen del Camino, Pamplona, Spain.
  • Rodríguez-Carballeira M; Deparment of Internal Medicine, Hospital Universitari Mútua Terrassa, Terrassa, Spain.
  • Rodríguez-Rodríguez L; Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain.
  • Camps T; Department of Internal Medicine, Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Castañeda S; Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain.
  • Alegre-Sancho JJ; Department of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain.
  • Martín J; Instituto de Parasitología y Biomedicina "López-Neyra", CSIC, PTS Granada, Granada, Spain.
  • González-Escribano MF; Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
Front Immunol ; 14: 1080047, 2023.
Article em En | MEDLINE | ID: mdl-37638008
ABSTRACT

Introduction:

The knowledge of the aetiology of Behçet disease (BD), an immune-mediated vasculitis, is limited. HLA-B, mainly HLA-B51, and HLA-A molecules are associated with disease, but the ultimate cause of this association remains obscure. There is evidence that NK cells participate in the etiopathology of BD. NK cells have activator and inhibitor surface receptors, like the KIR and the NKG2 families. Classical HLA-class I molecules (A, B and C) are keys in the activity control of the NK because they are KIR ligands. Most NKG2 receptors bind HLA-E, which presents only nonapeptides derived from the signal peptide of other class-I molecules.

Objective:

This study investigates the contribution of the pair HLA-E and ligand, nonapeptide derived from the 3-11 sequence of the signal peptides of class I classical molecules, to the susceptibility to BD.

Methods:

We analyzed the frequency of the HLA-derivated nonapeptide forms in 466 BD patients and 444 controls and an HLA-E functional dimorphism in a subgroup of patients and controls.

Results:

In B51 negative patients, the frequency of VMAPRTLLL was lower (70.4% versus 80.0% in controls; P=0.006, Pc=0.04, OR=0.60, 95%CI 0.41-0.86), and the frequency of VMAPRTLVL was higher (81.6% versus 71.4% in controls; P=0.004, Pc=0.03, OR=1.78, 95%CI 1.20-2.63). In homozygosity, VMAPRTLLL is protective, and VMAPRTLVL confers risk. The heterozygous condition is neutral. There were no significant differences in the distribution of the HLA-E dimorphism.

Discussion:

Our results explain the association of BD with diverse HLA-A molecules, reinforce the hypothesis of the involvement of the NK cells in the disease and do not suggest a significant contribution of the HLA-E polymorphism to disease susceptibility.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arterite de Células Gigantes / Granulomatose com Poliangiite / Síndrome de Behçet Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arterite de Células Gigantes / Granulomatose com Poliangiite / Síndrome de Behçet Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha